Therapeutics

2026 marks the first real entry of high risk medical devices into EU JCAs. From implantable prosthetics to active implantable devices, 15 categories have been identified as early candidates. This shift represents a maj...

Scientific rigor continues to shape payer expectations, and #AMCP2026 offers an important forum for advancing those standards. ICON will be at booth \#1412 to discuss approaches to robust evidence generation, real world ...

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our fr...

As ADCs expand into new indications—including rare cancers and potential autoimmune applications—regulatory pathways continue to adapt. ICON’s regulatory expert, Eilidh Mayer, examines how accelerated approvals, orphan ...

With increasing approvals across Asia and beyond, ADCs remain one of the most dynamic areas in oncology innovation. ICON’s new publication highlights the critical elements of regulatory engagement, dose optimisation and ...

Meet with ICON experts at the GLP-1-Based Therapeutics Summit to gain valuable insights on obesity clinical development and learn about our ready-to-deploy infrastructure designed to accelerate obesity and comorbidity pr...

ICON is heading to #AMCP2026 from 13–16 April, and our team is looking forward to engaging with leaders across the managed care and market access community. Visit us at booth \#1412 to learn how ICON’s evidence generatio...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - \~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pre...

Patient led organisations are actively shaping scientific and regulatory pathways in ultra rare diseases. Our recent webinar captured powerful examples of how real people are accelerating progress to meet needs, deliver ...

Thank you to everyone who joined our Rare Disease Day webinar. The inspiring discussion highlighted the results of patients’ and parents’ relentless advocacy, including scientific breakthroughs and regulatory progress in...

The U.S. multiple sclerosis treatment landscape is evolving—shifting from relapse suppression toward addressing disability progression in progressive forms of MS. New ICD 10 subtype codes, introduced in October 2025, ma...

Europe’s Health Technology Assessment Regulation officially went live in January 2025, marking a major shift toward harmonised JCAs and JSCs. What did we learn in year one? - The scale is growing fast – the number of JC...